Published in AIDS on December 03, 1998
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17
Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med (2000) 2.10
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol (2002) 1.36
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol (2009) 1.28
Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines (2008) 1.25
Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. J Infect Dis (2004) 1.11
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J Virol (2005) 1.05
Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog (2008) 0.95
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One (2011) 0.92
Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol (2008) 0.91
Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol (2005) 0.90
Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions. Retrovirology (2013) 0.83
Vaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+ T cells. Retrovirology (2011) 0.83
Polyvalent AIDS vaccines. Curr HIV Res (2010) 0.82
Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin Exp Immunol (2002) 0.81
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. J Acquir Immune Defic Syndr (2013) 0.81
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80
The development of an AIDS mucosal vaccine. Viruses (2010) 0.79
Host factors determine differential disease progression after infection with nef-deleted simian immunodeficiency virus. J Gen Virol (2014) 0.77
Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques. PLoS One (2013) 0.77
Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine. PLoS Pathog (2016) 0.75
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Ultrastructural features of Mycoplasma pneumoniae. J Bacteriol (1970) 3.84
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet (1995) 3.47
Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med (1996) 2.96
HIV counseling and testing of pregnant women in sub-Saharan Africa: experiences from a study on prevention of mother-to-child HIV-1 transmission in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr (2001) 2.81
Antibodies to brain and other tissues in cases of Mycoplasma pneumoniae infection. Clin Exp Immunol (1971) 2.76
Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Methods (1998) 2.31
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (1991) 2.28
Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol (1976) 2.24
Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med (1995) 2.23
Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet (1991) 2.10
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS (2000) 2.08
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (1987) 1.93
HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol (1986) 1.88
Mycoplasma pneumoniae is a polyclonal B-cell activator. Nature (1976) 1.83
Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol (1994) 1.77
Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults. J Clin Microbiol (1997) 1.76
Induction of immunoglobulin G Fc receptors by recombinant vaccinia viruses expressing glycoproteins E and I of herpes simplex virus type 1. J Virol (1990) 1.73
F-Actin-depolymerizing activity of human serum. Eur J Biochem (1979) 1.71
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71
Monitoring of HIV-1 infection prevalence and trends in the general population using pregnant women as a sentinel population: 9 years experience from the Kagera region of Tanzania. J Acquir Immune Defic Syndr (2000) 1.70
A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. AIDS Res Hum Retroviruses (1987) 1.67
Further immunological studies of sera containing anti-mitochondrial antibodies, type M 5. Clin Exp Immunol (1984) 1.63
Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol (1987) 1.61
Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses (1992) 1.60
Discrimination between antibodies to HIV and to related retroviruses using site-directed serology. Nature (1987) 1.59
Reaction of human smooth muscle antibodies with human blood lymphocytes and lymphoid cell lines. Nature (1974) 1.54
Blood donor sera with false-positive Western blot reactions to human immunodeficiency virus. Lancet (1986) 1.53
The mixed haemadsorption test as an aid to the diagnosis of thyroid autoimmune disease. Clin Exp Immunol (1968) 1.52
Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. Proc Natl Acad Sci U S A (1989) 1.48
Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection. AIDS Res Hum Retroviruses (1997) 1.48
Isolation of human immunodeficiency virus-related simian immunodeficiency viruses from African green monkeys. Proc Natl Acad Sci U S A (1989) 1.47
Lymphocyte subset enumeration in HIV seronegative and HIV-1 seropositive adults in Dar es Salaam, Tanzania: determination of reference values in males and females and comparison of two flow cytometric methods. J Immunol Methods (2003) 1.45
Antiviral cytotoxic T lymphocyte induction and vaccination. Rev Infect Dis (1988) 1.45
Genetic and environmental determination of human sleep. Sleep (1983) 1.44
Development of a quasispecies of human immunodeficiency virus type 1 in vivo. Proc Natl Acad Sci U S A (1992) 1.44
Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among old world primates? J Virol (2000) 1.44
Central nervous system complications of Mycoplasma pneumoniae infection. Scand J Infect Dis (1969) 1.41
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS (2005) 1.41
Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel. J Virol Methods (1998) 1.39
T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella. Infect Immun (1983) 1.37
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med (2000) 1.37
Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res Hum Retroviruses (1996) 1.36
Immunohistopathology of lymph nodes in HTLV-III infected homosexuals with persistent adenopathy or AIDS. Cancer Res (1985) 1.36
Performance of a modified HIV-1 p24 antigen assay for early diagnosis of HIV-1 infection in infants and prediction of mother-to-infant transmission of HIV-1 in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.34
Oral candida albicans in HIV infection. Scand J Infect Dis (1987) 1.31
Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area. AIDS (1997) 1.31
Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology (1996) 1.30
Immunological changes in primary HIV-1 infection. AIDS (1990) 1.30
Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology (2000) 1.29
Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. J Immunol Methods (1996) 1.27
Prevalence of HIV-1 infection in the Kagera region of Tanzania: a population-based study. AIDS (1990) 1.26
Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum (1987) 1.24
Reaction of human smooth muscle antibody with thyroid cells. Clin Exp Immunol (1974) 1.24
Simian immunodeficiency virus of African green monkeys is apathogenic in the newborn natural host. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.23
The effect of irradiation on T-cell suppression of ELISA-determined Ig production by human blood B-cells in vitro. Clin Exp Immunol (1979) 1.22
Reaction of human smooth muscle antibody with thymus medullary cells. Nat New Biol (1973) 1.22
Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol Microbiol Immunol Scand A (1987) 1.21
The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol (1994) 1.21
Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. AIDS (1999) 1.19
Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med (1986) 1.18
Smooth muscle antibodies in Mycoplasma pneumoniae infection. Clin Exp Immunol (1976) 1.17
Antibodies in bronchial secretions following natural infection with Mycoplasma pneumoniae. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 1.16
Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses (1997) 1.16
Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retroviruses (1991) 1.16
Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. J Acquir Immune Defic Syndr (1989) 1.16
Activation of human lymphocyte subpopulations by Mycoplasma pneumoniae. Scand J Immunol (1977) 1.14
The accuracy of an alternative confirmatory strategy for detection of antibodies to HIV-1: experience from a regional laboratory in Kagera, Tanzania. J Clin Virol (1999) 1.14
Lack of HIV-1 V3 region sequence diversity in two haemophiliac patients infected with a putative biologic clone of HIV-1. AIDS (1991) 1.14
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis (1996) 1.13
Site-directed ELISA with synthetic peptides representing the HIV transmembrane glycoprotein. J Med Virol (1987) 1.13
Circulating immune complexes in Mycoplasma pneumoniae infection. J Immunol (1974) 1.13
Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin Vaccine Immunol (2008) 1.13
High virus loads in naturally and experimentally SIVagm-infected African green monkeys. Virology (2001) 1.12
Acceptability of voluntary HIV testing with counselling in a rural village in Kagera, Tanzania. AIDS Care (1998) 1.11
Evaluation of commercial enzyme immunoassays for anti-HIV-1 using East African sera. AIDS (1988) 1.11
Specific and non-specific B cell activation in measles and varicella. Clin Exp Immunol (1983) 1.11
A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS (1993) 1.11
Lack of dichotomy between virus load of peripheral blood and lymph nodes during long-term simian immunodeficiency virus infection of African green monkeys. Virology (1996) 1.11
Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology (1993) 1.11
Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol (1997) 1.11